Elsevier

The Lancet

Volume 344, Issue 8935, 26 November 1994, Pages 1453-1457
The Lancet

Articles
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation

https://doi.org/10.1016/S0140-6736(94)90286-0Get rights and content

Abstract

Summary

We investigated whether the occurrence of venous thrombosis in young women who use oral contraceptives might be explained by the factor V Leiden mutation, which leads to resistance to activated protein C and enhances susceptibility to thrombosis.

We compared 155 consecutive premenopausal women, aged 15 to 49, who had developed deep venous thrombosis in the absence of other underlying diseases, with 169 population controls. The risk of thrombosis among users of oral contraceptives was increased 4-fold (relative risk 3·8 [95% Cl 2·4-6·0]). The risk of thrombosis among carriers of the mutation compared with non-carriers was increased 8-fold (7·9 [3·2-19·4]). Compared with women who did not use oral contraceptives and were not carriers of the mutation, the risk of thrombosis among those with both risk factors was increased more than 30-fold (34·7 [7·8-154]).

Recalculation of population incidences from these relative risks shows that the absolute risk of venous thrombosis in young women who use oral contraceptives is much larger when they carry the factor V Leiden mutation. When a young woman develops thrombosis, her factor V Leiden status should be considered in counselling about her future method of contraception.

References (30)

  • Bb Gerstman et al.

    Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease

    Am J Epidemiol

    (1991)
  • B. Dahlbäck et al.

    Familial thrombophilia due to a previously unecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C

    Proc Natl Acad Sci USA

    (1993)
  • Rm Bertina et al.

    Mutation in blood coagulation factor V associated with resistance to activated protein C

    Nature

    (1994)
  • Fr Rosendaal et al.

    Evaluation of activated protein C resistance in stored plasma

    Lancet

    (1994)
  • Cited by (1138)

    • Disorders of Hemostasis and Thrombosis

      2022, Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics: Hematologic, Renal, and Immunologic Disorders
    View all citing articles on Scopus
    View full text